Skip to main content

Advertisement

SpringerLink
Log in

Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods

  • Original Article
  • Published:
Molecular Diversity Aims and scope Submit manuscript

Abstract

In cancer disease, which is one of the problems of today’s human societies, the expression of some tyrosine kinase receptors that are effective in the growth and proliferation of cancerous cells rises. Therefore, it is essential to develop and propose new drugs to target the receptors. Performing modeling calculations such as QSAR and docking makes the drug discovery process more efficient. Thus, backpropagation artificial neural network was used for multidimensional quantitative structure–activity relationship (QSAR) to identify essential features of pyrazolopyrimidine moiety, responsible for anticancer activity. The statistical parameters of the model show that multi-QSAR has sufficient validity and accuracy. According to the QSAR modeling, among 26 compounds, the interaction of eight candidates with EGFR, FGFR4, PDGFRA, and VEGFR2 was analyzed by docking modeling. The results showed that 1u compound binds to proteins in a more appropriate area (except FGFR4) with acceptable energy. The results of docking for VEGFR2 binding showed that 1u binds to the active site and binding site of receptor, and it was in the interaction with ten residues in the sites. Although the binding site of 1u molecule in the FGFR4 was not suitable, the binding free energy was excellent (− 9.22 kcal mol−1), which was less than those two anticancer drugs of gefitinib and regorafenib. Furthermore, the values of binding free energy were − 8.69, − 9.64, and − 9.19 kcal mol−1 for EGFR, PDGFRA, and VEGFR2, respectively. Therefore, this study introduces 1u as an anticancer agent that can inhibit the tyrosine kinase receptors.

Graphic abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Siegel RL, Miller KD (2018) Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30

    Article  Google Scholar 

  2. Dorai T, Aggarwal BB (2004) Role of chemopreventive agents in cancer therapy. Cancer Lett 215(2):129–140

    Article  CAS  Google Scholar 

  3. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315(3):971–979

    Article  CAS  Google Scholar 

  4. Li E, Hristova K (2010) Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adh Migr 4(2):249–254

    Article  Google Scholar 

  5. Bahmani A, Saaidpour S, Rostami A (2017) A simple, robust and efficient computational method for n-octanol/water partition coefficients of substituted aromatic drugs. Sci Rep 7:5760–5774

    Article  Google Scholar 

  6. Slynko I, Scharfe M, Rumpf T, Eib J, Metzger E, Schüle R, Jung M, Sippl W (2014) Virtual screening of PRK1 inhibitors: ensemble docking, rescoring using binding free energy calculation and QSAR model development. J Chem Inf Model 54:138–150

    Article  CAS  Google Scholar 

  7. Chaube U, Chhatbar D, Bhatt H (2016) 3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer. Bioorg Med Chem Lett 26(3):864–874

    Article  CAS  Google Scholar 

  8. Dong H, Liu J, Liu X, Yu Y, Cao S (2018) Combining molecular docking and QSAR studies for modeling the anti-tyrosinase activity of aromatic heterocycle thiosemicarbazone. J Mol Struct 1151:353–365

    Article  CAS  Google Scholar 

  9. Masand VH, El-Sayed NNE, Bambole MU, Quazi SA (2018) Multiple QSAR models, pharmacophore pattern and molecular docking analysis for anticancer activity of α, β-unsaturated carbonyl-based compounds, oxime and oxime ether analogs. J Mol Struct 1157:89–96

    Article  CAS  Google Scholar 

  10. Engel J, Smith S, Lategahn J, Tumbrink HL, Goebel L, Becker C, Hennes E, Keul M, Unger A, Müller H, Baumann M, Schultz-Fademrecht C, Günther G, Hengstler JG, Rauh D (2017) Structure-guided development of covalent and mutant-selective pyrazolopyrimidines to target T790M drug resistance in epidermal growth factor receptor. J Med Chem 60(18):7725–7744

    Article  CAS  Google Scholar 

  11. Xu L, Zhang WJ (2001) Comparison of different methods for variable selection. Anal Chim Acta 446:477–483

    Article  CAS  Google Scholar 

  12. Bahmani A, Saaidpour S, Rostami A (2017) Quantitative structure–retention relationship modeling of morphine and its derivatives on OV-1 column in gas–liquid chromatography using genetic algorithm. Chromatographia 80(4):629–636

    Article  CAS  Google Scholar 

  13. Hosseinpour Moghadam N, Salehzadeh S, Shahabadi N, Golbedaghi R (2017) A multi-spectroscopic and molecular docking approach to investigate the interaction of antiviral drug oseltamivir with ct-DNA. Nucleosides Nucleotides Nucleic Acids 36(7):435–451. https://doi.org/10.1080/15257770.2017.1287379

    Article  CAS  Google Scholar 

  14. Salehzadeh S, Hajibabaei F, Hosseinpour Moghadam N, Sharifinia S, Khazalpour S, Golbedaghi R (2018) Binding studies of isoxsuprine hydrochloride to calf thymus DNA using multispectroscopic and molecular docking techniques. J Fluoresc 28(1):195–206

    Article  CAS  Google Scholar 

  15. Tanzadehpanah H, Asoodeh A, Saidijam M, Chamani J, Mahaki H (2017) Improving efficiency of an angiotensin converting enzyme inhibitory peptide as multifunctional peptides. J Biomol Struct Dyn, 1–16

  16. Cheng CT, Zhao MY, Chau KW, Wu XY (2006) Using genetic algorithm and TOPSIS for Xinanjiang model calibration with a single procedure. J Hydrol 316:129–140

    Article  Google Scholar 

  17. Head RD, Smythe ML, Oprea TI, Waller CL, Green SM, Marshall GR (1996) VALIDATE: a new method for the receptor-based prediction of binding affinities of novel ligands. J Am Chem Soc 118(16):3959–3969

    Article  CAS  Google Scholar 

  18. Lipkus AH (2001) Exploring chemical rings in a simple topological-descriptor space. J Chem Inf Model 41(2):430–438

    CAS  Google Scholar 

  19. Consonni V, Todeschini R, Pavan M (2002) Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors 1 theory of the novel 3D molecular descriptors. J Chem Inf Model 42(3):682–692

    CAS  Google Scholar 

  20. Deshpande S, Solomon VR, Katti SB, Prabhakar YS (2009) Topological descriptors in modelling antimalarial activity: N1-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine as prototype. J Enzyme Inhib Med Chem 24(1):94–104

    Article  CAS  Google Scholar 

  21. Todeschini R, Consonni V (2003) Descriptors from molecular geometry in Handbook of Chemoinformatics, vol 3. Wiley-VCH Verlag GmbH, Weinheim, Germany

    Google Scholar 

  22. Ritchie TJ, Macdonald SJF (2014) Physicochemical descriptors of aromatic character and their use in drug discovery. J Med Chem 57(17):7206–7215

    Article  CAS  Google Scholar 

  23. Todeschini R, Consonni V (2000) Handbook of molecular descriptors. Wiley-VCH Verlag GmbH, Weinheim, Germany

    Book  Google Scholar 

  24. Devinyak O, Havrylyuk D, Lesyk R (2014) 3D-MoRSE descriptors explained. J Mol Graph Model 54:194–203

    Article  CAS  Google Scholar 

  25. Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74

    Article  CAS  Google Scholar 

  26. Xu G, Searle LL, Hughes TV, Beck AK, Connolly PJ, Abad MC, Neeper MP, Struble GT, Springer BA, Emanuel SL (2008) Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorg Med Chem Lett 18(12):3495–3499

    Article  CAS  Google Scholar 

  27. Yewale C, Baradia D, Vhora I, Patil S, Misra A (2013) Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34(34):8690–8707

    Article  CAS  Google Scholar 

  28. Tanzadehpanah H, Mahaki H, Hosseinpour Moghadam N, Salehzadeh S, Rajabi O, Najafi R, Amini R, Saidijam M (2018) Binding site identification of anticancer drug gefitinib to HSA and DNA in the presence of five different probes. J Biomol Struct Dyn 1–14

  29. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6):1137–1149

    Article  CAS  Google Scholar 

  30. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 286(21):18756–18765

    Article  CAS  Google Scholar 

  31. Gupta AK, Bhunia SS, Balaramnavar VM, Saxena AK (2011) Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors. SAR QSAR Environ Res 22(3–4):239–263

    Article  CAS  Google Scholar 

  32. Noolvi MN, Patel HM (2013) A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design. J Saudi Chem Soc 17(4):361–379

    Article  CAS  Google Scholar 

  33. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217–227

    Article  CAS  Google Scholar 

  34. Ho HK, Yeo AHL, Kang TS, Chua BT (2014) Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov Today 19(1):51–62

    Article  CAS  Google Scholar 

  35. Cheng W, Wang M, Tian X, Zhang X (2017) An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. Eur J Med Chem 126:476–490

    Article  CAS  Google Scholar 

  36. Ho HK, Németh G, Ng YR, Pang E, Szantai-Kis C, Zsákai L, Breza N, Greff Z, Horvath Z, Pato J (2013) Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Curr Med Chem 20(10):1203–1217

    Article  CAS  Google Scholar 

  37. Mo C, Zhang Z, Guise CP, Li X, Luo J, Tu Z, Xu Y, Patterson AV, Smaill JB, Ren X (2017) 2-Aminopyrimidine derivatives as new selective fibroblast growth factor receptor 4 (FGFR4) inhibitors. ACS Med Chem Lett 8(5):543–548

    Article  CAS  Google Scholar 

  38. Liang L, Yan XE, Yin Y, Yun CH (2016) Structural and biochemical studies of the PDGFRA kinase domain. Biochem Biophys Res Commun 477(4):667–672

    Article  CAS  Google Scholar 

  39. Hasegawa M, Nishigaki N, Washio Y, Kano K, Harris PA, Sato H, Mori I, West RI, Shibahara M, Toyoda H (2007) Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem 50(18):4453–4470

    Article  CAS  Google Scholar 

  40. Ugale VG, Patel HM, Surana SJ (2017) Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3D QSAR and docking approach. Arab J Chem 10:S1980–S2003

    Article  CAS  Google Scholar 

  41. Munoz C, Adasme F, Alzate-Morales JH, Vergara-Jaque A, Kniess T, Caballero J (2012) Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model 32:39–48

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Funding

This work is a part of the research project and was financially supported by Deputy of Research, Hamadan University of Medical Sciences [Grant Number 9612158167]. Therefore, the authors are very thankful for the support of this deputy.

Author information

Author notes

  1. Massoud Saidijam

    Present address: Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

  2. Asrin Bahmani and Hamid Tanzadehpanah contributed equally to this work.

Authors and Affiliations

  1. Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

    Asrin Bahmani, Hamid Tanzadehpanah & Neda Hosseinpour Moghadam

Authors
  1. Asrin Bahmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Tanzadehpanah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neda Hosseinpour Moghadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massoud Saidijam
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

In this work, the authors had various responsibilities. A. Bahmani was responsible for proposing the project, doing QSAR-modeling, interpretation of QSAR, and writing QSAR for articles. N. Hosseinpour Moghadam was responsible for docking calculations. H. Tanzadehpanah was responsible for interpreting and writing of docking for the article. M. Saidijam led the research team and was responsible for editing and submitting the article to the journal.

Corresponding author

Correspondence to Massoud Saidijam.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bahmani, A., Tanzadehpanah, H., Hosseinpour Moghadam, N. et al. Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods. Mol Divers 25, 949–965 (2021). https://doi.org/10.1007/s11030-020-10080-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11030-020-10080-8

Keywords

Search

Navigation